BioAtla, Inc. (BCAB)
| Market Cap | 399.66M |
| Revenue (ttm) | 429,000 |
| Net Income (ttm) | -35.85M |
| Shares Out | 8.43M |
| EPS (ttm) | -3.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $47.42 |
| Previous Close | $47.74 |
| Change ($) | -0.32 |
| Change (%) | -0.67% |
| Day's Open | 48.00 |
| Day's Range | 46.22 - 48.08 |
| Day's Volume | 72,266 |
| 52-Week Range | 27.15 - 76.63 |
SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announ...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can b...
SAN DIEGO, Dec. 18, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics fo...
SAN DIEGO, Dec. 15, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics fo...
San Diego, California-based BioAtla was founded to develop conditionally active biologics that 'exploit characteristic pH differences between the tumor microenvironment and healthy tissue.'
BioAtla, a Phase 2 biotech developing antibody therapies for solid tumor cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
BioAtla, Inc. has filed to go public with an IPO on the New York Stock Exchange (NYSE).
About BCAB
BioAtla is a clinical-stage biopharmaceutical company developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Our conditionally active biologics, or CABs, capitalize on our proprietary discoveries with respect to tumor biology, enabling us to target known and widely validated tumor antigens that have previously been difficult or impossible to target. Our novel CAB therapeutic candidates exploit characteristic pH differences between the tumor microenvironment and healthy ti... [Read more...]
| Industry Biotechnology | IPO Date Dec 16, 2020 |
| CEO Jay M. Short | Employees 36 |
| Stock Exchange NASDAQ | Ticker Symbol BCAB |
Financial Performance
In 2020, BioAtla's revenue was $429,000, a decrease of -91.75% compared to the previous year's $5.20 million. Losses were -$35.85 million, 20.3% more than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for BioAtla stock is "Buy." The 12-month stock price forecast is 76.67, which is an increase of 61.68% from the latest price.